Availability of Poxel's 2022 Half-Year Financial Report
04 Ottobre 2022 - 5:45PM
Business Wire
POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage
biopharmaceutical company developing innovative treatments for
serious chronic diseases with metabolic pathophysiology, including
non-alcoholic steatohepatitis (NASH) and rare metabolic diseases,
today announces the publication of its half-year financial report
as of June 30, 2022.
The report includes:
- the consolidated financial statements for the first half of
2022 closed on June 30, 2022;
- the half-year activity report;
- the Statutory Auditors' limited review report on the half-year
information, which includes several observations;
- the certificate of the person responsible for the half-year
financial report.
The 2022 half-year financial report is available on the
Company's website.
Next financial press release: 2022 Third Quarter
Financial Update, on November 8, 2022.
About Poxel SA
Poxel is a clinical stage biopharmaceutical company
developing innovative treatments for chronic serious diseases
with metabolic pathophysiology, including non-alcoholic
steatohepatitis (NASH) and rare disorders. For the treatment of
NASH, PXL065 (deuterium-stabilized R-pioglitazone) met its
primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In
rare diseases, development of PXL770, a first-in-class
direct adenosine monophosphate-activated protein kinase (AMPK)
activator, is focused on the treatment of adrenoleukodystrophy
(ALD) and autosomal dominant polycystic kidney disease (ADPKD).
TWYMEEG® (Imeglimin), Poxel’s first-in-class product that
targets mitochondrial dysfunction, is now marketed for the
treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel
expects to receive royalties and sales-based payments. Poxel has a
strategic partnership with Sumitomo Pharma for Imeglimin in Japan,
China, and eleven other Asian countries. Listed on Euronext Paris,
Poxel is headquartered in Lyon, France, and has subsidiaries in
Boston, MA, and Tokyo, Japan.
For more information, please visit: www.poxelpharma.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221004005926/en/
Investor relations / Media
Aurélie Bozza Investor Relations & Communication Senior
Director aurelie.bozza@poxelpharma.com +33 6 99 81 08 36
Elizabeth Woo Senior Vice President, Investor Relations &
Communication elizabeth.woo@poxelpharma.com
NewCap Emmanuel Huynh or Arthur Rouillé poxel@newcap.eu +33 1 44
71 94 94
Grafico Azioni Poxel (EU:POXEL)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Poxel (EU:POXEL)
Storico
Da Apr 2023 a Apr 2024